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ABSTRACT 
 
 
 
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease of the axial skeleton. The 
major outcome of this disease is defined by new bone formation, commonly observed in the ligaments 
of the intervertebral joints, that can lead to the formation of bony spurs, known as syndesmophytes. 
Previous studies have shown that serum levels of TNF, IL-6 and IL-17 are increased in AS patients 
and may be implicated in the development of secondary osteoporosis, since these cytokines are able 
to induce osteoclast (OC) differentiation and, therefore, bone resorption. 
In this work we aimed to assess the effects of TNF-blocking therapy in the systemic inflammatory 
environment of AS patients with active disease as well as in OC differentiation and activity. To 
accomplish this objective, we cultured circulating monocytes from AS patients, before and after 
therapy, under osteoclastogenic conditions and we performed two functional assays (TRAP staining 
and resorption pit assay) and analyzed the expression of osteoclast specific genes. 
We have shown that AS patients with active disease have increased levels of pro-inflammatory 
cytokines when compared with healthy subjects. We also found that IL-17, TGF-β and osteoprotegerin 
are decreased after TNF-blocking therapy. Interestingly, we also observed that after TNF-blocking 
therapy the expression of some genes is favoring osteoclastogenesis and that differentiated OCs have 
increased resorption activity. 
These results suggest that in active AS there may be an uncoupling between inflammation and OC 
activity that is reset by TNF-blocking therapy. 
 
 
Keywords: ankylosing spondylitis, inflammation, osteoclastogenesis, TNF-blocking therapy 
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RESUMO 
 
 
 
A espondilite anquilosante (EA) é uma doença inflamatória crónica do esqueleto axial. A 
característica principal desta doença é o excesso de formação óssea observada principalmente nos 
ligamentos das articulações intervertebrais que é capaz de levar à formação de pontes ósseas, 
conhecidas por sindesmófitos, entre as vértebras. 
Estudos prévios mostraram que os níveis séricos de TNF, IL-6 e IL-17 estão aumentados em 
doentes com EA o que pode estar envolvido no desenvolvimento de osteoporose secundária, uma 
vez que estas citocinas são capazes de induzir a diferenciação de osteoclastos (OCs) e, 
consequentemente, a reabsorção óssea. 
Neste trabalho propusemo-nos a avaliar os efeitos de agentes biológicos que inibem o TNF no 
ambiente inflamatório sistémico de doentes com EA activa assim como na diferenciação e actividade 
dos OCs. Para isso, colocámos em cultura monócitos circulantes de doentes com EA antes e depois 
da terapia com anti-TNF sob condições osteoclastogénicas, fizemos dois ensaios funcionais 
(marcação da TRAP e ensaios de reabsorção) e analisámos a expressão de genes específicos dos 
osteoclastos. 
Com este estudo mostrámos que os doentes com EA activa têm níveis aumentados de citocinas 
pró-inflamatórias comparativamente aos controlos saudáveis e que depois da terapia com anti-TNF 
os níveis das citocinas IL-17, TGF-β e de osteoprotegerina estão diminuídos. Para além disto, ainda 
observámos que depois da terapia com anti-TNF a expressão de alguns genes tende a favorecer a 
osteoclastogénese e que os OCs diferenciados têm maior actividade reabsortiva.  
Estes resultados sugerem que na EA activa pode haver um mecanismo que desconecte a 
inflamação e a actividade dos OCs e a ligação entre estes dois processos pode ser reestabelecida 
pela terapia com anti-TNF. 
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I. INTRODUCTION 
 
 
 
1. Bone 
Bone is a dynamic connective tissue with an extracellular matrix composed of mineral, collagen, 
water, noncollagenous proteins and also lipids. It has two phases, a mineral phase essentially 
composed by inorganic particles of hydroxyapatite embedded in an organic matrix mainly composed 
of type 1 collagen fibers (Boskey and Robey 2013). The composition and organization of the bone 
matrix gives this tissue unique mechanical properties such as stiffness, rigidity, ductility, tensile 
strength and exceptional lightness (Burr and Akkus 2014). 
Apart from its mechanical role of supporting the whole body and allowing locomotion, bone also 
has many other important functions. It plays a protective role, shielding many vital organs and 
structures, like the bone marrow and spinal cord, and a metabolic role, regulating the homeostasis of 
calcium and phosphate. Bone is also a hematopoietic organ since it is a source of red blood cells and 
an endocrine organ, contributing to the global energy balance (Burr and Akkus 2014).  
There are three main cell types present in bone: (i) the osteoclasts (OCs), giant multinucleated 
cells derived from macrophage-monocyte lineage that resorb bone by dissolving bone mineral and by 
enzymatically degrading extracellular matrix proteins and which will be deeply discussed in the next 
chapter; (ii) the osteoblasts (OBs), cells of mesenchymal origin responsible for bone formation that are 
able to produce the organic bone matrix and aid its mineralization; (iii) and the osteocytes, mature 
osteoblasts that become entrapped in the bone matrix and act as mechanosensors, a crucial function 
in the regulation of bone remodeling (Crockett, Rogers et al. 2011; Del Fattore, Teti et al. 2012). 
 
1.1. Bone remodeling 
Bone remodeling is a dynamic process where bone undergoes continuous destruction and 
formation, that occurs continually at several sites throughout the skeleton in response to mechanical 
and metabolic effects. It relies on the accurate balance between bone resorption by OCs and bone 
formation by OBs, whose functions must be tightly coupled not only quantitatively, but also in time and 
space (Del Fattore, Teti et al. 2012). However, this coupling process is only precise in adulthood since 
during early life bone formation exceeds bone resorption leading to a increase in bone mass, and with 
ageing bone resorption exceeds bone formation with a decrease of bone mass (Sims and Gooi 2008). 
An imbalance in bone resorption and formation can lead to several bone pathological conditions such 
as osteoporosis, characterized by low bone mineral density (BMD) and increased resorption, or 
osteopetrosis characterized by excess bone formation that leads to high BMD (Teitelbaum and Ross 
2003). 
Osteoblast differentiation and function, and therefore bone formation, is under the control of bone 
morphogenetic proteins (BMPs) and Wingless (Wnt) signaling pathways (Crockett, Rogers et al. 
2011). BMPs belong to the transforming growth factor (TGF) beta superfamily and are involved in the 
early step of osteoblastogenesis (Del Fattore, Teti et al. 2012) whilst the canonical Wnt signaling 
I. INTRODUCTION 
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pathway is essential for osteoblast differentiation during skeletogenesis and continues to be important 
in mature osteoblasts (Crockett, Rogers et al. 2011). 
Sclerostin (SOST) is a secreted protein synthesized by bone cells that are in contact with the bone 
mineral, specifically, late-stage osteoblasts and osteocytes. In vitro, SOST has been shown to inhibit 
osteoblast proliferation, impair mineralization by osteoblasts and to stimulate osteoblast apoptosis by 
interfering with Wnt and BMP signaling (Winkler, Sutherland et al. 2003; Sutherland, Geoghegan et al. 
2004; van Bezooijen, Roelen et al. 2004). Therefore, SOST is capable of inhibiting bone formation 
(Crockett, Rogers et al. 2011). In addition to SOST, Dickkopf-1 (DKK-1) is also a soluble inhibitor of 
Wnt signaling pathway (Pinzone, Hall et al. 2009). 
Various biochemical markers are used to assess bone metabolism. Bone turnover markers can be 
classified as markers of bone resorption that may be associated with OC function or may reflect bone 
matrix degradation and, on the other hand, markers of bone formation that are associated with 
osteoblast function and with type 1 collagen assembly. The most used markers are C-terminal 
telopeptide of type 1 collagen (CTX-I) cleaved during bone resorption, and procollagen type 1 N 
propeptide (P1NP) for bone formation. During bone formation, procollagen is cleaved at the N- and C- 
terminal ends so P1NP reflects the rate of new bone formation (Coates 2013). 
 
 
2. Osteoclasts 
OCs are specialized cells capable of resorb mineralized bone and play a key role in the process of 
bone modeling and remodeling that maintains the bone tissue in a healthy state by the continuous 
repair of microfractures (Mellis, Itzstein et al. 2011). Mature OCs are multinucleated giant cells that 
express high levels of tartrate-resistant acid phosphatase (TRAP), which has been widely used as a 
cytochemical marker of OCs and their precursors (Igarashi, Lee et al. 2002).  
 
2.1. Osteoclastogenesis 
OCs are derived from mononuclear hematopoietic myeloid lineage cells, which are formed in the 
bone marrow. Osteoclast precursors (OCPs) are attracted from the bone marrow to the bloodstream 
by chemokines and circulate there until they are recruited to the bone surface where they can 
differentiate into mature OCs upon exposure to stimuli (Ishii, Kikuta et al. 2010).  When OCPs are 
attracted to the bone tissue they are exposed to chemokines and cytokines, such as macrophage 
colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kB ligand (RANKL). These 
cytokines are expressed by several cells, including osteoblasts, and are essential for OC 
differentiation (Boyce 2013). 
OCs are giant multinucleated cells formed by the fusion of mononuclear precursors of the 
macrophage-monocyte lineage. OC formation, survival and their unique ability to resorb bone are 
controlled by several signaling pathways. OC differentiation and survival can be influenced by multiple 
cytokines, but RANKL and M-CSF are essential during normal osteoclastogenesis (Wu, Humphrey et 
al. 2008).  
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The cytokine M-CSF is produced by osteoblasts and stromal cells and is critical in both OC 
differentiation and survival. M-CSF interacts with the c-fms tyrosine kinase receptor expressed on 
early OCPs, which is essential for their proliferation and survival (Kikuta and Ishii 2013) and stimulates 
the expression of RANK on these cells (Wu, Humphrey et al. 2008; Kikuta and Ishii 2013).  
RANKL exists both in a soluble and a membranous form with both active forms. The soluble form 
(sRANKL) corresponds to the c-terminal part of membranous RANKL that may be produced either 
directly by stromal cells or osteoblasts through an alternative splicing followed by a secretion in the 
extra-cellular medium, or by a proteolytic clivage of membranous RANKL by tumor necrosis factor 
(TNF) converting enzyme - TACE (Kwan Tat, Padrines et al. 2004). Membrane-bound RANKL is 
expressed on the cell surface of osteoblasts, bone marrow stromal cells, fibroblasts, mammary 
epithelial cells and activated immune system cells (Wu, Humphrey et al. 2008). RANKL binds to its 
receptor RANK, a member of the TNF receptor superfamily present on OCPs and mature OCs and 
stimulates OC differentiation (Kwan Tat, Padrines et al. 2004). RANKL also binds to another TNF 
receptor family member, osteoprotegerin (OPG), which is produced by osteoblasts, bone marrow 
stromal cells, immune system cells and is a soluble molecule that inhibits osteoclastogenesis by acting 
as a decoy receptor for RANKL (Wu, Humphrey et al. 2008). The ratio of RANKL and OPG is critical 
for controlling OC differentiation and its bone-resorptive function (Kikuta and Ishii 2013) (Fig.I.1). 
Upon binding to RANKL, RANK initiates several downstream signaling cascades through the 
essential adapter molecule TNF receptor-associated factor 6 (TRAF6), since RANK itself does not 
have kinase activity (Mellis, Itzstein et al. 2011). TRAF6 leads to activation of some critical 
transcription factors like nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), 
mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and activator protein 1 
(AP-1) proteins c-Fos and c-Jun which are required for OC differentiation (Novack and Teitelbaum 
2008). The target gene for both NF-kB and c-Fos in OCPs is nuclear factor of activated T cells 
cytoplasmic 1 (NFATc1), that has been proposed to function as the master transcription factor in 
osteoclastogenesis (Takayanagi, Kim et al. 2002). Also, activation of RANK signaling by RANKL leads 
to expression of genes required for the fusion of mononuclear OCPs, such as dendritic cell specific 
transmembrane protein (DC-STAMP), as well as of genes required for regulating the resorptive 
capacity of multinucleated OCs, including those encoding the vacuolar ATPase, the chloride/H
+
 
antiporter channel CLC7 and cathepsin K (Fig.I.1) (Mellis, Itzstein et al. 2011).  
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Figure I.1 - Osteoclast differentiation is dependent on RANKL and M-CSF. RANKL and M-CSF are produced, 
among other cells, by osteoblasts. These cytokines bind to their receptors, RANK and c-fms, respectively, which 
are present in osteoclasts precursors, inducing osteoclastogenesis. OPG is also produced by osteoblasts and 
acts as a decoy receptor for RANKL. Hence, the ratio of sRANKL/OPG is crucial for controlling osteoclast 
differentiation. Some genes expressed during osteoclastogenesis are also represented. CSF1R - Colony 
stimulating factor 1 receptor; RANK - receptor activator of nuclear factor-kB; NFATc1 - Nuclear factor of activated 
T-cells cytoplasmic 1; Atp6v0d2 - ATPase; CLCN7 - chloride channel ; CTSK - cathepsin K; RANKL - receptor 
activator of nuclear factor-kB ligand; M-CSF - macrophage colony-stimulating factor; c-fms - receptor of M-CSF; 
OPG - osteoprotegerin Adapted from (Nakashima and Takayanagi 2009). 
 
 
2.2. Bone resorption 
Bone resorption occurs in three stages: OC attachment to the bone matrix and cell polarization, 
initiation of resorption and cessation of resorption.  
OC attachment to the bone surface is mainly dependent on integrins, in particular the vitronectin 
receptor - αVβ3 integrin (Mellis, Itzstein et al. 2011) - that recognizes the aminoacid motif Arg-Gly-Asp 
(RGD), a component of bone matrix proteins such as osteopontin (OPN) (Novack and Teitelbaum 
2008). αVβ3 integrin mediates OC motility, adhesion to the bone matrix required for polarization of the 
resorptive machinery and formation of an isolated, acidified resorptive microenvironment. The mature 
OC is rich in mitochondria and is significantly polarized, with its nuclei localized in the opposite 
direction to the resorptive surface (Novack and Teitelbaum 2008). After attachment, and consequently 
polarization, osteoclasts organize their actin cytoskeleton into an actin ring in order to form a sealing 
zone (Luxenburg, Geblinger et al. 2007). They also develop integrin-mediated adhesion structures 
called podosomes which are columnar arrays of actin that are of major importance in bone resorption 
and osteoclast motility (Luxenburg, Geblinger et al. 2007; Takahashi, Ejiri et al. 2007). Due to 
podosome formation, the membrane enclosed by the sealing zone becomes a highly convoluted 
ruffled membrane where protons are transported by the vacuolar ATPase and proteases are secreted 
to demineralize and degrade the bone matrix, respectively (Fig.I.2) (Mellis, Itzstein et al. 2011). The 
ruffled membrane is formed by podosomes and by the fusion of acidic vesicles of the 
endocytic/lysosomal pathway that transport the resorption machinery such as cathepsin K, TRAP, 
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vacuolar ATPase and the Cl
-
/H
+
 antiporter channel CLC7 to the plasma membrane in direct contact 
with bone (Mellis, Itzstein et al. 2011). The resorptive space is highly acidified and this acidification 
process is initiated by carbonic anhydrase (CA) which generates H
+
 and HCO3
-
 ions (Fig.I.2). The 
protons (H
+
) are transported out of the osteoclast and into the resorption lacuna by a proton pump 
(H
+
ATPase) and a chloride channel (CLCN7) charge-coupled to H
+
ATPase that acts as a chloride-
proton antiporter (transports Cl
−
 into the resorptive lacuna). Hence, OCs need both functional 
H
+
ATPase and CLCN7 in order to acidify the underlying resorption lacuna (Lee 2010). Intracellular pH 
is maintained by a Cl
−
/HCO3
-
 exchanger on the osteoclast's antiresorptive surface (Novack and 
Teitelbaum 2008) (Fig.I.2).  
 
 
 
Figure I.2 - Bone resorption by osteoclasts. Osteoclast attach to bone surface through αVβ3 integrins to form a 
sealing zone. This surrounds a highly convoluted ruffled membrane which is responsible for bone resorption. The 
resorptive lacune is acidified by carbonic anhydrase (CA) which supplies protons for the proton pump 
(H
+
ATPase). TRAP and cathepsin K regulate bone matrix resorption and collagen turnover. Intracellular pH is 
maintained by a Cl
−
/HCO
3-
 exchanger on the OCs surface. In turn, electroneutrality is maintained by a ruffled 
membrane-located chloride channel (CLCN7) charge-coupled to the H
+
ATPase, that transports Cl
−
 into the 
resorptive lacuna.  Adapted from (Lee 2010). 
 
 
TRAP is a soluble acid resistant phosphatase secreted by the OC and has a functional involvement 
in bone resorption, although its physiological substrates have not been identified yet. The candidates 
are phosphorylated tyrosine, sugar-phosphates as ATP, mannose-6-phosphates and bone matrix 
phosphoproteins, such as phosphorilated-OPN. Another possible function for TRAP is generating 
highly destructive reactive oxygen species (ROS) capable of destroying collagen and other proteins 
(Igarashi, Lee et al. 2002). The resorptive lacunae is highly acidified reaching a pH sufficiently low to 
dissolve the mineral phase, which occurs prior to degradation of the bone organic matrix, that consists 
mainly of type 1 collagen, by cathepsin K (Novack and Teitelbaum 2008).   
Type 1 collagen degradation by cathepsin K releases CTX-I fragments (Borel, Gineyts et al. 2012). 
Once degraded, bone matrix products like CTX-I and calcium ions (Ca
2+
), are internalized by 
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endocytosis in the central area of the ruffled membrane and are then transported to the functional 
secretory domain, opposed to the resorbing area, to be secreted. This mechanism allows OCs to 
remove large amounts of matrix-degradation products without losing their tight attachment to the 
underlying bone (Mellis, Itzstein et al. 2011).  
When the calcium released from the bone surface is in higher concentration levels surrounding the 
OC, it leads to an inhibition of resorption as a consequence of disruption of cytoskeletal structures. 
Once the calcium concentration is diluted, the OC repolarizes and assembles a new sealing zone. 
OCs are highly motile cells and are able to migrate from one site of resorption to a new one. Their 
capacity to achieve this function is made possible by the ability to disassemble and reassemble their 
podosomes quickly. Optimal bone resorption depends upon these cycles of attachment, sealing zone 
formation and migration (Mellis, Itzstein et al. 2011). 
 
2.3. Inflammation and osteoclast 
Several systemic and local factors have been reported to influence osteoclasts and bone 
resorption. In a pathological condition with excessive activation of the immune system, such as 
inflammation, there are additional pro-inflammatory cytokines produced mainly by activated T cells. 
These cytokines are osteoclastogenic if they stimulate osteoclast differentiation or anti-
osteoclastogenic if they inhibit osteoclasts (Zupan, Jeras et al. 2013).  
A wide range of pro-inflammatory cytokines is produced by lymphocytes, macrophages and 
neutrophils during inflammation (Novack and Teitelbaum 2008). Among them is tumor necrosis factor 
(TNF), a multifunctional cytokine that plays a key role in host defense after infection or tissue injury 
and is also particularly important because it is one of the most potent osteoclastogenic cytokines 
produced in inflammation. It has been reported that TNF increases c-fms expression (Cho, Lee et al. 
2010) and RANK expression in OCPs (Kitaura, Sands et al. 2004). TNF also stimulates RANKL 
signaling to induce expansion and differentiation of OCP cells and acts on non-hematopoietic cells 
such as stromal and endothelial cells to induce M-CSF and RANKL expression (Kwan Tat, Padrines et 
al. 2004; Gengenbacher, Sebald et al. 2008). Besides TNF, there are other pro-inflammatory 
cytokines, such as interleukin (IL)-1, IL-6 and IL-17 which induce osteoclastogenesis since they act on 
osteoblasts to promote RANKL expression (Schett 2008; Zupan, Jeras et al. 2013). 
OCs are key in inflammation-associated bone loss in rheumatic diseases and therefore, TNF-
induced osteoclastogenesis is probably essential to the pathogenesis of disorders involving 
inflammation (Kitaura, Kimura et al. 2013).  
 
 
3. Ankylosing spondylitis 
Spondyloarthritis (SpA) are a diverse group of inter-related inflammatory arthritis that share multiple 
clinical features such as inflammatory back pain, asymmetrical peripheral oligoarthritis (mainly of the 
lower limbs), enthesitis and specific organ involvement such as anterior uveitis, psoriasis and chronic 
inflammatory bowel disease. The most common SpA is ankylosing spondylitis (AS), a chronic and 
severe inflammatory disease of unknown etiology that affects primarily the axial skeleton and 
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sacroiliac joints. AS affects between 0.1 and 1.4% of the Caucasian population, with a incidence of 
about 7.3 per 100 000 people per year (Bakland and Nossent 2013). It affects mainly young people at 
around 26 years of age and is more common in men than women, at a 2:1 ratio (Feldtkeller, Khan et 
al. 2003).   
Characteristic symptoms of AS are morning stiffness, loss of spinal mobility, pain and fatigue which 
can be explained by spinal inflammation, structural damage, or both, and can lead to a decrease in 
quality of life, affecting patient's work, family and social activities and also increasing the risk of 
depression (Braun and Sieper 2007; Bond 2013). The strongest known contributing genetic factor for 
AS is the major histocompatibility complex (MHC) class I molecule HLA-B27 (Sheehan 2004). This 
antigen is critical for the presentation of antigen-derived peptides to cytotoxic CD8 T cells (Braem and 
Lories 2012). 90-95% of AS patients are positive for HLA-B27, however only about 5% of HLA-B27-
positive subjects are at the risk of developing the disease suggesting that other genes might be 
involved in disease susceptibility (Zambrano-Zaragoza, Agraz-Cibrian et al. 2013).  
AS outcome is defined, apart from chronic inflammation, by new cartilage and bone formation. 
Osteoproliferation can lead to the formation of bone spurs known as syndesmophytes when they are 
originated inside a ligament. Syndesmophytes are commonly seen in the ligaments of the 
intervertebral joints, which may result in the progressive ankylosis of the sacroiliac joints and the spine 
and in the fusion of the vertebrae leading to the appearance of a bamboo spine, a radiographic feature 
typical of this disease (Braem and Lories 2012) (Fig.I.3). 
The major question in the molecular pathophysiology of AS is how inflammation and structural 
damage interact. Although AS is a disease characterized by excessive bone formation, it is also an 
inflammatory disease which is commonly associated with bone loss. This might seems rather 
paradoxal but osteopenia and/or osteoporosis is a common complication of AS, even in the early 
stages of disease (Bronson, Walker et al. 1998; El Maghraoui 2004). The formation of 
syndesmophytes occurs at the same location of resolved inflammatory lesions however there is no 
evidence of correlation between inflammation and new bone formation in AS (Schett, Coates et al. 
2011). 
It has been shown that systemic inflammatory mediators, such as TNF, IL-1, IL-6 and IL-17, play a 
role in modulating bone turnover in AS. Serum levels of TNF, IL-6 and IL-17 are increased in patients 
with AS which may be implicated in the development of secondary osteoporosis, since they are able to 
induce OC differentiation (Gratacos, Collado et al. 1994; Appel, Loddenkemper et al. 2009). Moreover, 
it has also been shown that OC number is increased in the bone of AS patients during acute stages of 
inflammation (Appel, Kuhne et al. 2006). 
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Figure I.3 - Ankylosing spondylitis outcome. Ankylosing spondylitis is a chronic inflammatory disease that affects 
mainly joints of the spine and sacroiliac joints and can cause fusion of the vertebrae in the spine. Adapted from 
(StemRx 2012) 
 
3.1. Diagnosis and assessment 
Diagnosis of AS patients is in accordance with the 1984 Modified New York criteria (see Appendix, 
Table VI.1), which includes radiographic evidence of sacroiliac joint changes and also clinical 
parameter of inflammatory back pain (van der Linden, Valkenburg et al. 1984).   
To assess disease activity in patients with AS there are two major tools: the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score 
(ASDAS). The BASDAI is a questionnaire based on the patients’ perception of fatigue, pain and 
stiffness. This index has limitations since they are fully patient oriented. ASDAS combines patient-
reported assessments (like back pain, duration of morning stiffness, patient global assessment of 
disease activity, peripheral pain or swelling) and also acute phase reactants such as C-reactive 
protein (CRP) or, in alternative, erythrocyte sedimentation rate (ESR) (Ramiro 2011). The Bath 
Ankylosing Spondylitis Functional Index (BASFI) is used to evaluate the degree of functional limitation 
in AS patients and it is a questionnaire based on the patients’ ability to perform several activities (Irons 
2009). 
 
3.2. Treatment 
Non-steroidal anti-inflammatory drugs (NSAIDs) are highly effective in reducing symptoms as 
inflammation and acute and chronic pain and are considered a first-line therapy for AS (Poddubnyy 
and van der Heijde 2012). Biologic therapies such as anti-TNF drugs have been a great advance in 
the treatment of AS and have become the standard of care for AS patients.  
Currently, inhibition of TNF is considered the most effective approach for reducing symptoms of 
inflammation and improving the clinical assessment in AS patients (Coates, Marzo-Ortega et al. 2010). 
At the moment, there are five biologic agents targeting TNF for patients with active AS with two 
different mechanisms of action: monoclonal antibodies against TNF and a recombinant TNF receptor 
fusion protein (Baraliakos and Braun 2012).  Monoclonal antibodies against TNF such as the chimeric 
monoclonal IgG1 antibody infliximab, and the fully humanized monoclonal antibodies adalimumab and 
golimumab are antibodies with a constant human IgG1 region (Fc) and a variable region (Fv) which 
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have the capacity to specifically bind to the soluble and transmembrane forms of TNF. Besides these, 
studies of certolizumab, another monoclonal TNF blocker, are being performed. The recombinant 
75kD TNF receptor IgG1 fusion protein etanercept acts by inhibiting TNF binding to the cell-surface 
receptors, making TNF biologically inactive and impeding the cell responses mediated by TNF (Silva, 
Ortigosa et al. 2010). 
It is described that anti-TNF therapy is able to halt mechanisms driving cartilage and bone 
destruction (Hreggvidsdottir, Noordenbos et al. 2014). However, recent studies found that in AS 
patients with TNF inhibition, ectopic bone formation is still observed, suggesting that additional factors 
are governing this effect (Schett, Coates et al. 2011; Taylan, Sari et al. 2012; Osta, Benedetti et al. 
2014). Moreover, patients have decreased CTX-I levels after TNF-blocking therapy, with increased 
bone mineral density (BMD) in lumbar spine (Arends, Spoorenberg et al. 2012). 
 
 
4. Aim 
AS is characterized by syndesmophyte formation and increased BMD in the lumbar spine. In 
patients under TNF-blocking treatment a reduction of CTX-I levels was reported (Arends, Spoorenberg 
et al. 2012), which might reflect a decrease in osteoclast activity. Therefore, we hypothesize that there 
is an impairment in OC differentiation and activity in AS patients with active disease, that might be 
further inhibited by TNF-blocking therapy. 
Our objectives were to understand how anti-TNF therapy regulates inflammatory environment in 
AS patients. Moreover we wanted to understand TNF-blocking effects on OC differentiation and 
activity in AS patients.  
We performed cytokine and bone turnover marker analysis and also ex vivo differentiation of OCs 
from circulating monocytes from AS patients before and after TNF-blocking treatment. OC functional 
assays, microscopy studies, gene expression, were also performed in order to understand the effects 
of TNF antagonists in OC differentiation and activity. 
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II. MATERIALS AND METHODS 
 
 
 
1. Patients 
Patients who fulfilled the 1984 Modified New York criteria for AS followed up at the Department of 
Rheumatology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, EPE, were included in this 
study. None of the recruited AS patients was under any biological disease modifying anti-rheumatic 
drug (DMARD) at the time of enrolment and all of them started TNF-blocking therapy at the time of 
first blood collection. For each patient a blood sample was collected for peripheral blood mononuclear 
cells (PBMCs) isolation and serum storage. All patients signed an informed consent and filled a clinical 
questionnaire to assess demographical and clinical characteristics such as symptoms duration, ESR, 
CRP, presence of sacroiliitis, ASDAS, BASDAI, BASFI and HLA-B27 status. Patients under NSAIDs 
and DMARDs were not excluded from this study. These patients were followed up for a minimum of 
six months, when a second blood sample was collected. 
A group of age and sex-matched controls was also included and a blood sample was collected in 
order to isolate PBMCs and for serum storage. 
This study did not affected the regular follow-up of the patients. This project was approved by the 
ethical committee of Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, EPE, and all 
proceedings were performed in accordance with the declaration of Helsinki, as amended in Fortaleza, 
2013 (WMA 2013). 
 
2. PBMC isolation  
PBMCs from AS patients and control subjects were isolated by density gradient centrifugation. 
Heparinized peripheral blood was diluted with phosphate buffered saline (PBS) 1x and then carefully 
laid over Ficoll-Paque (Histopaque 1077, Sigma-Aldrich, USA). The density gradient was centrifuged 
at 980g for 35 minutes at room temperature in a swinging-bucket rotor without acceleration or brake. 
The mononuclear cell layer (including lymphocytes and monocytes) was then collected and washed 
twice with PBS 1x. The viable cells were counted in an haemocytometer using trypan blue 0.1% 
(Sigma-Aldrich, USA). 
 
3. Cell culture 
The isolated PBMCs were cultured in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, UK) 
previously supplemented with 5000 U Penicilin/Streptomicin (Invitrogen, UK), 2 mM L-Glutamin 
(Invitrogen, UK) and 10% Fetal Bovine Serum (FBS; Invitrogen, UK) in both 96 and 24 well flat bottom 
plates (Nunc, German) and incubated in a humidified atmosphere at 37ºC, 5% CO2. Cells were plated 
in 96-well culture plates at a density of 7.0x10
5
 cells/well and in 24-well culture plates at a density of 
1.5x10
6
 cells/well.  
Cells cultured in 24 well-plates were used for RNA extraction at the first day of culture. In the 96-
well culture plates, cells were seeded on top of bovine cortical bone slices (Immuno Diagnostic 
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Systems Ltd, UK) to extract RNA and to perform functional assays (TRAP staining and resorption pit 
assay) at days 7, 14 and 21 of culture (Fig.II.1A).  
PBMCs were left overnight for OCPs to adhere on bone slices (Holloway, Collier et al. 2002). On 
the following day (day 1 of culture) medium was changed. Two culture conditions were then created, a 
control condition with DMEM only (hence called unstimulated) and a stimulated condition with DMEM 
supplemented with M-CSF 25 ng/mL (Peprotech, Rocky Hill, NJ). Three days later, medium was again 
changed and in the stimulated condition DMEM was supplemented with M-CSF (25 ng/mL), sRANKL 
(50 ng/mL; Peprotech, Rocky Hill, NJ), dexamethasone (10 nM; Sigma Aldrich, St. Louis, MO) and 
TGF-β (2.5 ng/mL; R&D Systems, Minneapolis, MN) in order to differentiate the osteoclast precursors 
into mature osteoclasts (Fig.II.1B) (Takuma, Kaneda et al. 2003).  
 
 
Figure II.1 - A Design of 24 and 96-wells culture plates. Cells cultured in 24 well-culture plates with 
unstimulated (Unstim) condition (DMEM only) used for RNA collection of first day of culture and in 96-well plates 
with both unstimulated and stimulated (Stim) condition (with M-CSF, RANKL, dexamethasone and TGF-β) in 
order to collect RNA from cells and to perform functional assays (TRAP staining and resorption assay) at days 7, 
14 and 21. B Experimental design. Isolated PBMCs were plated under a stimulated condition, DMEM 
supplemented with M-CSF during the first four days of culture and after that with M-CSF, RANKL, 
dexamethasone and TGF-β until day 21. 
 
The culture medium was then changed twice a week. Cells cultured on bone slices for 7, 14 and 21 
days (Holloway, Collier et al. 2002; Husheem, Nyman et al. 2005) were used for functional assays and 
one well per condition, per time-point was collected for RNA extraction. 
 
4. Functional assays 
 
4.1. TRAP staining 
Tartrate-resistant acid phosphatase (TRAP) is a cytoplasmic enzyme that is highly expressed by 
osteoclasts (Igarashi, Lee et al. 2002).  
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TRAP staining of pre-OCs and OCs was performed using the Acid Phosphate, Leukocyte Kit 
(TRAP, Sigma-Aldrich, St. Louis, MO) according to manufacturer's instructions. Cells are fixated briefly 
with a fixative solution with paraformaldehyde 4% and incubated with TRAP substrate. Acid 
phosphatase hydrolyzes the substrate naphthol AS-BI phosphoric acid which couples with a dye such 
as fast garnet GBC producing a red precipitate at the site of the enzyme activity (Rodak, Fritsma et al. 
2007). After staining, the cell cytoplasm develops a red colour while the nuclei remains unstained. This 
assay allows the distinction between pre-OCs (with only one or two nuclei) and mature OCs 
(containing three or more nuclei).  
Bone slices from both TRAP staining and resorption functional assay were photographed with the 
brightfield microscope Leica DM2500 (Leica, Germany) under a 10x magnification objective. 
In the TRAP assay, the number of TRAP-positive cells (pre-OCs - with <3 nuclei - or OCs with ≥3 
nuclei per cell) was counted at five sites of the bone slice with the area of 1296x972µm each. Both 
osteoclast precursors and mature osteoclasts were manually counted for each time-point per condition 
using ImageJ software (NIH, Bethesda, MD). 
 
4.2. Resorption assay 
For measurement of resorbed area in the resorption assay, the bone slices were washed with PBS 
1x, incubated in 5% sodium hypochlorite for 15 minutes and incubated with 0.1% toluidine blue 
(Sigma-Aldrich, St. Louis, MO) for 2 minutes in the dark. 
The resorption pits are acidic structures and therefore will develop a blue to purple colour 
(Sridharan and Shankar 2012). 
In this assay, quantification of resorption pits was done at five sites of the bone slice with the area 
of 1296x972µm and were manually traced using ImageJ (NIH, Bethesda, MD), a mean value of the 
resorb area was also calculated and expressed in %. 
 
5. Gene expression 
 
5.1. RNA extraction and quantification 
RNA was extracted from cells at days 1, 7, 14 and 21 of culture and both from unstimulated and 
stimulated (M-CSF, RANKL, Dexamethasone and TGF-β) conditions using NZYol (NZYTech, Lda. 
Portugal) according to the manufacturer's instructions. NZYol is a ready-to-use reagent for the 
isolation of total RNA from cells and tissues since it is capable of disrupting cells, exposing their 
cellular components, and maintaining the integrity of the extracted RNA (NZYtech 2013). Cells 
disrupted in NZYol are incubated with chloroform (VWR, Radnor, PA) and centrifuged. After 
centrifugation the organic phase containing nucleic acids is transferred to a new tube and incubated 
with isopropyl alcohol (VWR, Radnor, PA) to precipitate RNA. RNA is then washed with ethanol 75% 
and finally solubilised in RNase/DNase free water (Gibco, Grand Island, NY). 
Following RNA extraction, total RNA concentration and purity was quantified using Nanodrop 1000 
(Thermo Scientific, Waltham, MA). RNA was stored at -80ºC until further use. 
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5.2. cDNA synthesis 
Complementary (c)DNA was synthesized at a concentration of 0.6 ng/µL using the DyNAmo™ 
cDNA Synthesis Kit (Thermo Scientific, Waltham, MA) according to the manufacturer's instructions.  
cDNA was synthesized from 0.6ng/uL of total RNA using the reverse transcriptase M-MuLV RNase H
+
 
and random hexamers. According to the protocol, cDNA synthesis occurs at 37ºC for 30 minutes, 
followed by the reaction termination, which occurs at 85ºC for 5 minutes in order to inactivate the 
reverse transcriptase M-MuLV RNase H
+
 to prevent it from inhibiting qPCR reaction. cDNA was stored 
at 4ºC. 
 
5.3. qPCR and gene expression quantification 
Gene expression was studied by quantitative PCR (qPCR), which provides quantitative and real-
time analysis of DNA samples from different sources.  
Genes that encode for osteoclast proteins such as CSF1R, RANK, NFATc1, ATP6v0d2, CLCN7 
and CTSK were studied. Ribossomal RNA 18s (rRNA 18s) was chosen as the housekeeping gene. 
Primers were designed using the primer-BLAST (Ye, Coulouris et al. 2012) software and having into 
consideration amplicon size less than 100bp, 60ºC annealing temperature and exon-exon junction, 
which was used to exclude unprocessed mRNA or possible genomic DNA contamination. Primer 
sequences and characteristics can be found in Appendix, Table VI.2. 
The DyNAmo™ Flash SYBR Green qPCR Kit (Thermo Scientific, Waltham, MA) was used 
according to the manufacturer's instructions. SYBR Green binds to the double stranded amplified 
product of qPCR and emits fluorescence, which is then detected by the thermocycler's detector 
(Corbett Rotor-Gene 6000, Qiagen, Netherlands). Briefly 1.8ng of cDNA are used for the PCR. The 
cycling reaction starts with an initial denaturation at 95ºC for 7 minutes to ensure a complete 
reactivation of the hot-start DNA polymerase and denaturation of the cDNA template, followed by a 
denaturation at 95ºC for 10 seconds. After these, a combined annealing and extension for 45 seconds 
at 60ºC was performed for fifty cycles. The reactions were validated by the presence of a single peak 
in the melt curve analysis. In order to analyze the results the Corbett Rotor-Gene 6000 Series 
Software 1.7 (Qiagen, Netherlands) was used.  
The efficiency of qPCR was analysed using the standard curve method. For each primer pair, a 
standard curve was made using as standard RNA trabecular bone samples from subjects with normal 
bone mineral density (BMD) and without risk factors for osteoporosis or other bone-related diseases. 
The initial DNA quantity was 30ng and then serial 1:5 dilutions down to 0.24ng were used for the 
standard curve. qPCR results were analyzed using the standard curve method. The cycle threshold 
(Ct) is defined as the number of cycles required for the fluorescent signal to cross the threshold and 
exceed the background level. The efficiency of the qPCR should be 100%, meaning that for each 
cycle, the amount of product doubles. A good reaction should have an efficiency of 90-100%, which 
corresponds to a slope between -3.58 and -3.10. The conversion of the Ct value in relative expression 
levels was performed with the slope and the Y intersect extracted from the standard curve and 
applying the equation 10
(Ct-Y intersect)/slope 
(Wong and Medrano 2005). The values obtained were 
normalized with the housekeeping gene 18s rRNA. 
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6. Cytokine and bone turnover marker quantification 
Serum levels of cytokines and bone turnovers markers were evaluated in the serum of both AS 
patients and control subjects. 
Soluble (s)RANKL, OPG, DKK-1, SOST, CTX-I and P1NP levels were measured in the serum by 
sandwich enzyme-Linked Immunosorbent Assay (ELISA) (sRANKL, OPG, DKK-1 and SOST from 
Biomedica, Vienna, Austria; CTX-I and P1NP from SunRed Biological Technology, Shangai, China). 
For cytokines found in serum, such as interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-
17A, IL-18, IL-22, IL-23, interferon (IFN)-γ, macrophage inflammatory protein (MIP)-1α, monocyte 
chemotactic protein (MCP)-1, tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β, 
the multiple analyte detection kit Flow Cytomix (eBioscience, San Diego, CA) was used according to 
the manufacturer's instructions. This assay is based on the ELISA method, however the capture 
antibody is conjugated with a microbead. Data was acquired on a LSR Fortessa II (BD Biosciences, 
Franklin Lakes, NJ) and was analyzed using FlowCytomix Pro 2.3 Software (eBioscience, San Diego, 
CA). 
 
7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 Software (GraphPad Software, Inc., La 
Jolla, CA). Data is represented as median [interquartile range]. For two variable comparison t-test or 
Mann-Whitney test were used according to normality distribution. For paired variables Wilcoxon 
matched pairs test was also used. For more than two variables Kruskall-Wallis test was used with 
post-hoc Dunn's test. Categorical variables are expressed as relative frequencies and to test them the 
Chi-Square test was used. p-values lower than 0.05 were considered statistically significant.  
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III. RESULTS 
 
 
 
1. Patient characteristics 
This study included 24 patients diagnosed with AS, 13 men and 11 women, with a median age of 
41 [35.25-47.25] years and with a median duration of symptoms of 10 [6.5-18.5] years, as shown in 
table III.1. Twelve of the 24 patients were followed-up for at least six months after the beginning of 
TNF-blocking therapy. One patient was only included at follow-up. 
Twenty-three healthy age and gender matched subjects were also included in this study, 13 males 
and 10 females with a median age of 41 [34.50-52.00] years.  
As shown in table III.1, half of patients at baseline and 46.15% at follow-up were positive for HLA-
B27. Most AS patients (83.33% at baseline) have sacroiliitis (seen by x-ray or MRI) and 33.33% of 
baseline patients have peripheral involvement. 
 
Table III.1 - Demographic and clinical data of ankylosing spondylitis patients. 
Ankylosing spondylitis patients 
Age (years) 41 [35.25-47.25] 
Symptoms duration (years) 10 [6.5-18.5] 
 
Baseline 
N=24 
Follow-up 
N=13 
p value 
Gender (F:M) 11:13 4:9 p=0.4908 
HLA-B27 (% positive) 50% 46.15% p=1.0000 
Sacroiliitis (% yes) 83.33% 84.62% p=1.0000 
Peripheric involvement (% yes) 33.33% 38.46% p=1.0000 
NSAIDs (% yes) 75% 69.23% p=0.7158 
DMARDs (% yes) 50% 46.15% p=1.0000 
Corticosteroids (% yes) 8.33% 7.69% p=1.0000 
ESR (mm/h) 26 [13-48] 7 [4-15] p=0.0001 
CRP (mg/dl) 0.72 [0.11-1.91] 0.13 [0.04-0.47] p=0.043 
ASDAS 3.4 [2.6-4] 1.75 [1.35-1.95] p<0.0001 
BASDAI 5.5 [4.1-7.4] 3.2 [1.6-4.05] p<0.0001 
BASFI 5.89 [3.60-7.55] 3.90 [1.39-5.20] p=0.0323 
Results are expressed in median [interquartile range 25-75]. Results were analyzed with unpaired 
student's t test or Mann-Whitney test. p-values lower than 0.05 are considered statistically significant. 
F - female; M - male; NSAIDs - non-steroidal anti-inflammatory drugs; DMARDs - disease-modifying 
anti-rheumatic drugs; ESR - erythrocyte sedimentation rate; CRP - C-reactive protein; ASDAS - 
ankylosing spondylitis disease activity score; BASDAI - bath ankylosing spondylitis disease activity 
index; BASFI - bath ankylosing spondylitis functional index. 
 
The majority (75%) of patients at baseline were under NSAIDs, whereas DMARDs were given to 
half of patients at baseline. Corticosteroids were the least common treatment for these patients, with 
only 8.33% of baseline patients receiving it (Table III.1). Both inflammatory markers, ESR and CRP, 
were significantly decreased in follow-up patients when compared to baseline (p=0.0001 and p=0.043, 
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respectively). ASDAS, BASDAI and BASFI were also significantly decreased after anti-TNF therapy 
(p<0.0001 for ASDAS and BASDAI and p=0.0323 for BASFI).  
When we consider only the 12 paired AS patients, which were included both at baseline and follow-
up, the median age is 40 [35.25-49.50] years with a median symptoms duration of 10 [7-21] years, as 
shown in table III.2. This group included 8 men and 4 women and 41.67% of patients were positive for 
HLA-B27. 
 
 
Table III.2 - Demographic and clinical data of paired ankylosing spondylitis patients. 
Paired ankylosing spondylitis patients (N=12) 
Age (years) 40 [35.25-49.50] 
Symptoms duration (years) 10 [7-21] 
Gender (F:M) 4:8 
HLA-B27 (% positive) 41.67% 
Sacroiliitis (% yes) 91.67% 
Peripheric involvement (% yes) 41.66% 
NSAIDs (% yes) 75% 
DMARDs (% yes) 66.67% 
Corticosteroids (% yes) 8.33% 
  Baseline Follow-up p-value 
ESR (mm/h) 36.50 [15.25-53.75] 9 [4-15.75] p=0.0036 
CRP (mg/dl) 1.43 [0.18-3.22] 0.12 [0.04-0.50] p=0.0049 
ASDAS 3.85 [2.30-4.28] 1.8 [1.5-2] p=0.0006 
BASDAI 4.45 [3.73-7.65] 2.85 [1.53-4.08] p=0.0018 
BASFI 6.19 [4.6-7.6] 3.9 [1.07-5.3] p=0.0048 
Results are expressed in median [interquartile range 25-75]. Results were analyzed with paired 
student's t test or Wilcoxon matched pairs test. p-values lower than 0.05 are considered statistically 
significant. F - female; M - male; NSAIDs - non-steroidal anti-inflammatory drugs; DMARDs - disease-
modifying anti-rheumatic drugs; ESR - erythrocyte sedimentation rate; CRP - C-reactive protein; 
ASDAS - ankylosing spondylitis disease activity score; BASDAI - bath ankylosing spondylitis disease 
activity index; BASFI - bath ankylosing spondylitis functional index. 
  
Sacroiliitis is present in 91.67% of these patients and 41.66% also have peripheral involvement. 
75% of the patients were under NSAIDs, 66.67% DMARDs and only 8.33% corticosteroids. 
As shown in table III.2, both ESR and CRP are significantly decreased after anti-TNF therapy. ESR 
decreased from 36.50 [15.25-53.75] mm/h at baseline to 9 [4-15.75] mm/h at follow-up (p=0.0036) and 
CRP diminishes from 1.43 [0.18-3.22] mg/dl to 0.12 [0.04-0.50] mg/dl after TNF-blocking therapy 
(p=0.0049). 
ASDAS, BASDAI and BASFI have a significant decrease after anti-TNF therapy (table III.2). 
ASDAS significantly decreased from 3.85 [2.30-4.28] to 1.8 [1.5-2] at follow-up (p=0.0006), BASDAI 
was reduced from 4.45 [3.73-7.65] to 2.85 [1.53-4.08] after TNF-blocking therapy (p=0.0018) and 
likewise BASFI decreased from 6.19 [4.6-7.6] at baseline to 3.9 [1.07-5.3] at follow-up (p=0.0048). 
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2. Cytokine, chemokine and bone turnover markers in circulation 
It is known that the cytokine milieu has a major influence on the osteoclast activity and on bone 
resorption. 
Pro-inflammatory cytokines as IL-6, IL-1β and TNF levels are all significantly elevated in untreated 
AS patients in comparison to controls (IL-6 p=0.0002; IL-1β p=0.0001; TNF p=0.0014) as seen in 
Fig.III.1. Although levels of these three cytokines are also lower in follow-up patients when compared 
to baseline there were no significant differences. Levels of IL-23 were also increased in the baseline 
when compared with follow-up patients and healthy subjects, but the differences were not statistically 
significant (Fig.III.1). 
 
Figure III.1 - Serum levels of IL-6, IL-1β, IL-23 and TNF of ankylosing spondylitis patients at baseline of anti-TNF 
therapy, follow-up six months after starting the therapy and healthy donors. Bars represent median values. 
Results were analyzed with Kruskal-Wallis test. p-values lower than 0.05 are considered statistically significant. 
**p<0.01, ***p<0.001. IL – interleukin; TNF - tumor necrosis factor. 
 
 
The levels of pro-inflammatory cytokines IL-12p70 and IL-17A were significantly increased in the 
baseline group when compared to healthy subjects (IL-12p70 p=0.0025; IL-17A p=0.0013). IL-22 
levels were significantly different when the three groups are compared (p=0.0494), showing higher 
levels at the baseline and follow-up groups in relation to controls (Fig.III.2). 
The levels of IL-12p70 and IL-22 were very similar between baseline and follow-up patients. The 
levels of IL-17A were decreased after anti-TNF therapy when compared to baseline but the difference 
was not statistically significant when comparing all groups. 
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Figure III.2 - Serum levels of IL-12p70, IL-17A and IL-22 of ankylosing spondylitis patients at baseline of anti-TNF 
therapy, follow-up six months after starting the therapy and healthy donors. Bars represent median values. 
Results were analyzed with Kruskal-Wallis test. p-values lower than 0.05 are considered statistically significant. 
*p<0.05, **p<0.01. IL – interleukin. 
 
 
 
As shown in Fig.III.3, chemokines as MCP-1, MIP-1α, IL-8 and IL-18 were all significantly 
increased in baseline AS patients when compared to healthy subjects (MCP-1 p=0.0074; MIP-1α 
p=0.0218; IL-8 p=0.0004; IL-18 p<0.0001). These chemokine levels were diminished in the follow-up 
group in comparison to the baseline group, but differences were not statistically significant. 
IL-18 concentration was significantly higher both at baseline (p<0.0001) and in AS patients treated 
with anti-TNF therapy (p<0.0001), as compared with controls (Fig.III.3).  
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Figure III.3 - Serum levels of MCP-1, MIP-1α, IL-8 and IL-18 of ankylosing spondylitis patients at baseline of anti-
TNF therapy, follow-up six months after starting the therapy and healthy donors. Bars represent median values. 
Results were analyzed with Kruskal-Wallis test. p-values lower than 0.05 are considered statistically significant. 
*p<0.05, **p<0.01, ***p<0.001. MCP-1 - monocyte chemotactic protein-1; MIP-1α - macrophage inflammatory 
protein-1α; IL – interleukin. 
 
 
 
The cytokines TGF-β, IFN-γ and IL-2 levels were all significantly different between baseline and 
healthy groups (TGF-β p=0.0060; IFN-γ p<0.0001; IL-2 p<0.0001), with significant higher levels in AS 
patients (Fig.III.4). Cytokine levels were decreased in follow-up patients when compared to the 
baseline, but without reaching statistical significance when all groups are compared. 
MCP-1
Baseline Follow up Healthy
0
5.0×103
1.0×104
1.5×104
2.0×104
**
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
M
C
P
-1
 (
p
g
/m
l)
MIP-1alpha
Baseline Follow up Healthy
0
5.0×103
1.0×104
1.5×104
2.0×104
2.5×104 *
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
M
IP
-1
a
lp
h
a
 (
p
g
/m
l)
IL-8
Baseline Follow up Healthy
0
5.0×102
1.0×103
1.5×103
2.0×103 ***
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
IL
-8
 (
p
g
/m
l)
IL-18
Baseline Follow up Healthy
0
1.0×104
2.0×104
3.0×104
4.0×104 ***
***
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
IL
-1
8
 (
p
g
/m
l)
III. RESULTS 
 
22 
 
 
Figure III.4 - Serum levels of TGF-β, IFN-γ and IL-2 of ankylosing spondylitis patients at baseline of anti-TNF 
therapy, follow-up six months after starting the therapy and healthy donors. Results were analyzed with Kruskal-
Wallis test. p-values lower than 0.05 are considered statistically significant. Bars represent median values. 
**p<0.01, ***p<0.001. TGF-β - transforming growth factor-β; IFN-γ - interferon-γ; IL – interleukin. 
 
 
 
Measuring anti-inflammatory cytokines IL-4 and IL-10 levels, we observed that baseline patients 
have significantly higher levels than healthy subjects (IL-4 p=0.0003; IL-10 p=0.0001), as seen in 
Fig.III.5. Moreover, both IL-4 and IL-10 were decreased in the follow-up group in relation to baseline, 
but the differences were not statistically significant (Fig.III.5). 
 
Figure III.5 - Serum levels of IL-4 and IL-10 of ankylosing spondylitis patients at baseline of anti-TNF therapy, 
follow-up six months after starting the therapy and healthy donors. Results were analyzed with Kruskal-Wallis 
test. p-values lower than 0.05 are considered statistically significant. Bars represent median values.***p<0.001. IL 
– interleukin. 
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sRANKL levels were slightly increased in AS patients at baseline when compared to follow-up or 
controls but without reaching statistical significance. Analyzing OPG levels there were no differences 
between groups when all groups are compared. (Fig.III.6).  
The sRANKL/OPG ratio is also lower at follow-up and in healthy subjects compared with the 
baseline group but no significant differences were found. 
 
Figure III.6 - Serum levels of sRANKL and OPG of ankylosing spondylitis patients at baseline of anti-TNF 
therapy, follow-up six months after starting the therapy and healthy donors. The ratio between sRANKL and OPG 
was calculated. Results were analyzed with Kruskal-Wallis test. p-values lower than 0.05 are considered 
statistically significant. Bars represent median values. sRANKL – soluble receptor activator of NF-kB; OPG – 
osteoprotegerin. 
 
 
 
Baseline AS patients have increased DKK-1 levels when compared with follow-up and healthy 
subjects, but the difference was not statistically significant. Additionally, SOST levels were very similar 
between the three groups (Fig.III.7). 
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Figure III.7 - Serum levels of DKK-1 and SOST of ankylosing spondylitis patients at baseline of anti-TNF therapy, 
follow-up six months after starting the therapy and healthy donors. Results were analyzed with Kruskal-Wallis 
test. p-values lower than 0.05 are considered statistically significant. Bars represent median values. DKK-1 – 
Dickkopf-related protein 1; SOST – sclerostin. 
  
 
 
As shown in Fig.III.8, CTX-I and P1NP levels were similar between baseline and follow-up patients. 
In healthy subjects, the levels of these two bone turnover markers were higher but without statistical 
significance. The same was observed in the CTX-I/P1NP ratio. 
 
Figure III.8 - Serum levels of CTX-1 and P1NP of ankylosing spondylitis patients at baseline of anti-TNF therapy, 
follow-up after starting the therapy six months and healthy donors. The ratio between CTX-1 and P1NP was 
calculated. Results were analyzed with Kruskal-Wallis test. p-values lower than 0.05 are considered statistically 
significant. Bars represent median values. CTX-I - C-terminal telopeptide of type 1 collagen; P1NP - procollagen 
type 1 N propeptide. 
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When we compared the paired AS patients before and after TNF-blocking therapy, we observed 
that the levels of IL-17A, TGF-β and OPG were significantly decreased after anti-TNF therapy when 
compared to baseline (IL-17A p=0.0195; TGF- β p=0.0186; OPG p=0.0425; Fig.III.9) 
 
Figure III.9 - Serum levels of IL-17A, TGF-β and OPG of paired AS patients at baseline of anti-TNF therapy and  
follow-up six months after starting the therapy and healthy donors. Median values are represented in the graphs. 
Results were analyzed with a Wilcoxon matched pairs test. p-values lower than 0.05 are considered statistically 
significant. *p<0.05. IL – interleukin; TGF-β - transforming growth factor-β; OPG – osteoprotegerin; AS - 
ankylosing spondylitis. 
 
 
 
3. Functional assays 
To understand the effect of TNF-blocking therapy in osteoclastogenesis, ex vivo functional assays 
were performed in cells cultured under unstimulated and stimulated (M-CSF (25 ng/mL), sRANKL (50 
ng/mL), dexamethasone (10 nM) and TGF-β (2.5 ng/mL)) conditions. 
 
3.1. Pre-osteoclast and osteoclast counts 
After TRAP staining the cell cytoplasm develops a red colour while the nuclei remains unstained 
which allows us to differentiate between pre-osteoclasts (with only one or two nuclei) and osteoclasts 
(containing three or more nuclei). In Fig.III.10 we can observe these two types of cells, where the blue 
arrows correspond to pre-osteoclasts and red arrows to mature osteoclasts. 
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Figure III.10 - Representative image of pre-osteoclasts (blue arrows) and mature osteoclasts (red arrows) 
observed by TRAP staining. The scale bar corresponds to 100μm. 
 
Pre-osteoclasts are defined as TRAP positive cells, with less than 3 nuclei (Fig.III.10 and III.11). 
Figure III.11 shows representative images of all groups in the selected time-points for the 
unstimulated condition. 
 
Figure III.11 - Unstimulated cells of baseline patients before TNF-blocking therapy, follow-up patients after six 
months of therapy and healthy donors. At time-points 7, 14 and 21 of culture TRAP staining was performed and 
photographs were taken with 10x objective. Representative images are shown for each time-point and condition. 
Blue arrows correspond to pre-osteoclasts. The scale bar corresponds to 100μm.  
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The number of pre-osteoclasts was counted both in the unstimulated and stimulated conditions and 
at days 7, 14 and 21 of culture. As seen in Fig.III.12, pre-osteoclast number decreased over time both 
in the unstimulated and stimulated conditions, although it did not reached statistical significance. 
 
 
 
 
 
Figure III.12 - Number of pre-osteoclasts of ankylosing spondylitis patients at baseline of anti-TNF therapy, 
follow-up six months after starting the therapy and healthy donors. These cells were cultured in unstimulated and 
stimulated conditions and TRAP staining was performed at days 7, 14 and 21 of culture. Pre-osteoclast number 
was counted and median values are represented in the graphs. Unstim - unstimulated condition; Stim - stimulated 
condition. 
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Osteoclasts are defined as large TRAP positive cells with 3 or more nuclei (Fig.III.10 and III.13).  
Figure III.13 shows representative images of all groups in the selected time-points for the 
stimulated condition. 
 
 
Figure III.13 - Stimulated cells of baseline patients before TNF-blocking therapy, follow-up patients after six 
months of therapy and healthy donors. Cells were cultured with stimuli (M-CSF, sRANKL, dexamethasone and 
TGF-β) and at time-points 7, 14 and 21 of culture TRAP staining was performed and photographs were taken with 
10x objective. Representative images are shown for each time point and condition. Blue arrows correspond to 
pre-osteoclasts and red arrows to mature osteoclasts. The scale bar width corresponds to 100μm.  
 
 
No significant differences were found in OC number between groups, both in unstimulated and 
stimulated conditions (Fig.III.14).  
In the unstimulated condition, despite there were no cytokines present, a few osteoclasts were 
formed at days 14 and 21 in the three groups (Fig.III.14, left panel).  
In the stimulated condition (Fig.III.14, right panel), baseline and follow-up groups reached the 
maximum number of OC at day 14, however controls only reached it at day 21 of culture. In follow-up 
group the number of OC was significantly different (p=0.0062) between days 7 and 14 and also 
between days 7 and 21. In the healthy group, we found a statistically significant increased between 
the number of OC at day 7 and at day 21 (p=0.0194).  
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Figure III.14 - Number of osteoclasts of ankylosing spondylitis patients at baseline of anti-TNF therapy, follow-up 
six months after starting the therapy and healthy donors. Cells were cultured with unstimulated and stimulated 
conditions and TRAP staining was performed at days 7, 14 and 21 of culture. Osteoclast number was counted 
and median values are represented in the graphs. Unstim - unstimulated condition; Stim - stimulated condition. 
  
 
The number of nuclei per osteoclast were also counted but no significant differences were found 
between groups, both in unstimulated and stimulated condiitons (Fig.III.15). 
 
Figure III.15 - Number of nuclei per osteoclast of ankylosing spondylitis patients at baseline of anti-TNF therapy, 
follow-up six months after starting the therapy and healthy donors. Cells were cultured with unstimulated and 
stimulated conditions and TRAP staining was performed at days 7, 14 and 21 of culture. Nuclei were counted and 
median values are represented in the graphs. Unstim - unstimulated condition; Stim - stimulated condition; OC - 
osteoclast. 
 
 
 
3.2. Resorption assays 
Resorption pits are acidic structures that develop a blue to purple colour after being incubated with 
toluidine blue which allows the measurement of the resorbed area (Fig.III.16). 
Figure III.16 shows representative images of all groups in the time-points where resorption pits 
were observed for the stimulated condition. 
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Figure III.16 - Resorption pits of baseline patients before TNF-blocking therapy, follow-up patients after six 
months of therapy and healthy donors. Cells were cultured in stimulation condition (with M-CSF, sRANKL, 
dexamethasone and TGF-β) and at time-points 7, 14 and 21 of culture resorption pit assay was performed and 
photographs were taken with 10x objective. Representative images are shown for each group at days 14 and 21 
of culture. Red arrows point to resorption pits.  The scale bar width corresponds to 100μm.  
 
As shown in Fig.III.17, upper panel, the three groups in study exhibit the same pattern over time 
regarding the number of resorption pits and the percentage of resorbed area, since both the number of 
resorption pits and the percentage of resorbed area tend to significantly increase over time (number of 
resorption pits: baseline p=0.0292; follow-up p=0.0002: healthy p=0.0140 and percentage of resorbed 
area: baseline p=0.0258; follow-up p=0.0003; healthy p=0.0119). 
In the unstimulated condition, despite osteoclasts were formed in the three groups (as shown 
previously in Fig.III.14) only one follow-up patient at day 21 showed resorption pits (data not shown).  
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No resorption pits were observed at day 7 in any group in the stimulated condition neither at day 14 
in the healthy group. No significant differences were found between groups neither in the number of 
resorption pits nor in the percentage of resorbed area when all groups are compared (Fig.III.17, upper 
panel).  
The resorbed area per pit increased from day 14 to day 21 both in baseline and follow-up patients, 
but the difference was not statistically significant (Fig.III.17, bottom left panel).  
As seen in Fig.III.17, bottom right panel, the baseline group has less resorption pits per OC than 
the follow-up and healthy groups at day 21 in the stimulated condition although this difference is not 
statistically significant. 
 
Figure III.17 - Number of resorption pits and percentage of resorbed area of ankylosing spondylitis patients at 
baseline of anti-TNF therapy, follow-up six months after starting the therapy and healthy donors. Cells were 
cultured with unstimulated and stimulated conditions and resorption pit assay was performed at days 7, 14 and 21 
of culture. No resorption pits were found in the unstimulated condition. The ratio between the resorbed area per 
pit was calculated. Number of resorption pits per osteoclasts of ankylosing spondylitis patients at baseline of anti-
TNF therapy, follow-up six months after starting the therapy and healthy donors in the stimulated condition at day 
21 of culture is also represented. Median values are represented in the graphs. Bars also represent median 
values. Results were analyzed with a Kruskal-Wallis test. p-values lower than 0.05 are considered statistically 
significant. Stim - stimulated condition; OC - osteoclast. 
 
 
 
When we compared the paired AS patients before and after TNF-blocking therapy, we found that 
both the number of resorption pits and the percentage of resorbed area are increased in follow-up 
patients when compared to the baseline (p=0.0469; Fig.III.18). 
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Figure III.18 - Number of resorption pits and percentage of resorbed area of paired ankylosing spondylitis 
patients at baseline of anti-TNF therapy and follow-up six months after starting the therapy and of healthy donors 
at day 21. Median values are represented in the graphs. Results were analyzed with a Wilcoxon matched pairs 
test. p-values lower than 0.05 are considered statistically significant. *p<0.05. Stim - stimulated condition. 
 
 
4. Gene expression analysis 
Since we found that osteoclast activity is increased after TNF-blocking therapy gene expression 
was analysed in cultured cells at days 1, 7, 14 and 21 of culture. 
At day 1 of culture cells were not stimulated yet, therefore the gene expression for this day 1 is the 
same in both culture conditions. 
 
CSF1R is expressed on monocytes and OCPs and is essential for the proliferation and survival of 
OCPs (Kikuta and Ishii 2013). 
In the unstimulated condition, at day 7 of culture, CSFR1 expression was significantly higher in the 
follow-up group and lower in the baseline group (p=0.0486; Fig.III.19, left panel). There was also a 
statistically significant increase of CSF1R expression over time in the baseline and follow-up groups, 
both between day 1 and 14 or 21 of culture (baseline p<0.0001; follow-up p=0.0002) and at the 
baseline a significant increased is also observed between day 7 and days 14 and 21 (p<0.0001). The 
CSF1R expression in the healthy group was also increasing over time although the differences did not 
reach statistical significance (Fig.III.19, left panel). 
In the stimulated condition, there were no differences between groups in the selected time-points. 
However all groups showed a significant increase in the CSF1R expression between days 1 and 7 of 
culture (baseline p=0.0026; follow-up p=0.0080; healthy p=0.0086) and day 7 is the time-point with the 
highest expression of this gene. Although there is a decrease in CSFR1 expression between day 7 
and 14 in all groups, there is still a significant difference in CSF1R relative expression between day 1 
and day 14 in the follow-up group (p=0.0080; Fig.III.19, right panel).   
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Figure III.19 - CSF1R relative expression in cultured cells of ankylosing spondylitis patients at baseline of anti-
TNF therapy, follow-up six months after starting the therapy and healthy donors. Cells were cultured with and 
without stimuli during 1, 7, 14 and 21 days. Median values are represented in the graphs. *p<0.05. CSF1R - 
Colony stimulating factor 1 receptor; Unstim - unstimulated condition; Stim - stimulated condition. 
 
 
RANK gene encodes for the receptor for RANKL present on monocytes and OCPs and mature 
OCs that stimulates OC differentiation (Kwan Tat, Padrines et al. 2004). 
As shown in Fig.III.20, RANK relative expression at day 1 was significantly lower in the follow-up 
patients when compared to healthy subjects (p=0.0026) and to baseline patients (p=0.042). 
In the unstimulated condition, the baseline and follow-up groups have an increase of RANK at day 
14, with a significant difference in expression between days 1 and 14 (baseline p=0.0024; follow-up p= 
0.0168). In the healthy subjects group, RANK expression decreases between days 1 and 7, but after 
day 7 RANK expression continues to increase until day 21, with a significant difference between days 
7 and 14 (p=0.0306; Fig.III.20, left panel). 
When cells were cultured under stimuli, the baseline group peaks at day 14 (p=0.0005), the follow-
up group at day 7 and the healthy group at day 1 (p=0.0079). RANK was not expressed at day 21 in 
the healthy group (Fig.III.20, right panel). 
 
 
Figure III.20 - RANK relative expression in cultured cells of ankylosing spondylitis patients at baseline of anti-TNF 
therapy, follow-up six months after starting the therapy and healthy donors. Cells were cultured with and without 
stimuli during 1, 7, 14 and 21 days. Median values are represented in the graphs. **p<0.01. RANK - Receptor 
activator of NF-kB; Unstim - unstimulated condition; Stim - stimulated condition. 
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NFATc1 is the target gene for RANK signaling cascade and has been proposed to function as the 
master transcription factor in osteoclastogenesis (Takayanagi, Kim et al. 2002).  
At day 1 of culture NFATc1 relative expression is significantly lower in follow-up patients than in 
healthy subjects (p=0.0096; Fig.III. 21).  
When cells are cultured without any stimuli, NFATc1 expression significantly increased in all 
groups between days 7 and 14 (baseline p=0.0027; follow-up p=0.0035; healthy p=0.0161; Fig.III.21, 
left panel). 
On the other hand, in the stimulated condition, the peak of NFATc1 expression occurs earlier than 
in unstimulated condition at day 7, reaching statistical significance when comparing to day 1 culture 
(baseline p=0.0038; follow-up p=0.0003; healthy p=0.0129; Fig.III.21, right panel). 
 
 
Figure III.21 - NFATc1 relative expression in cultured cells of ankylosing spondylitis patients at baseline of anti-
TNF therapy, follow-up six months after starting the therapy and healthy donors. Cells were cultured with or 
without stimuli during 1, 7, 14 and 21 days. Median values are represented in the graphs. **p<0.01. NFATc1 - 
Nuclear factor of activated T cells cytoplasmic 1; Unstim - unstimulated condition; Stim - stimulated condition. 
 
 
Atp6v0d2 gene encodes the subunit d2 of the functional domain v0 of the ATPase protein. This 
ATPase is responsible for extracellular acidification of the resorption lacunae and bone 
demineralization during bone resorption (Qin, Cheng et al. 2012). 
As seen in Fig.III.22, Atp6v0d2 expression at day 1 was significantly lower in follow-up patients 
compared with healthy subjects (p=0.0048) and with baseline patients (p=0. 042). 
In the unstimulated condition, at day 14, Atp6v0d2 expression was significantly higher in follow-up 
patients that in healthy subjects when all groups are compared (p=0.0261; Fig.III.22, left panel). Over 
time, in the baseline group Atp6v0d2 expression peaks at day 14 (p=0.0008) while in follow-up and 
healthy groups peaks at day 21 (follow-up p=0.0031; healthy p=0.026; Fig.III.22, left panel). 
Under the stimulated condition, Atp6v0d2 expression peaks at day 14 for baseline and healthy 
groups (baseline p=0.0014; healthy p=0.0017) but in the follow-up group the Atp6v0d2 expression 
continues to increase significantly until day 21 (p=0.0019; Fig.III.22, right panel). 
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Figure III.22 - Atp6v0d2 relative expression in cultured cells of ankylosing spondylitis patients at baseline of anti-
TNF therapy, follow-up six months after starting the therapy and healthy donors. Cells were cultured with or 
without stimuli during 1, 7, 14 and 21 days. Median values are represented in the graphs. *p<0.05, **p<0.01. 
Atp6v0d2 - ATPase; Unstim - unstimulated condition; Stim - stimulated condition. 
 
 
CLCN7 encodes for the chloride channel that maintains osteoclasts' electroneutrality and provides 
the chloride conductance required for an efficient proton pump (Novack and Teitelbaum 2008). 
As shown in Fig.III.23, CLCN7 relative expression at day 1 was significantly lower in follow-up 
patients than in healthy subjects (p=0.0131). 
In the unstimulated condition at day 7 CLCN7 relative expression was significantly higher in follow-
up when compared to baseline patients (p=0.0259; Fig.III.23, left panel). A significant increase in 
CLCN7 expression was also observed at day 14 in the baseline patients when compared to the 
healthy group (p=0.0346; Fig.III.23, left panel). Analyzing the results overtime, we observed that the 
baseline group has the highest CLCN7 expression at day 14 (p=0.002) but in the follow-up group 
CLCN7 peaks at day 21, although without statistical significance (Fig.III.23, left panel). 
When cells were cultured with stimuli, both baseline and follow-up groups showed the highest 
CLCN7 expression at day 7 (baseline p=0.0163; Fig.III.23, right panel). 
In the healthy group, both in unstimulated as well as in stimulated conditions, CLCN7 expression 
peaks at day 1 and decreased overtime (Fig.III.23). 
 
 
Figure III.23 - CLCN7 relative expression in cultured cells of ankylosing spondylitis patients at baseline of anti-
TNF therapy, follow-up six months after starting the therapy and healthy donors. Cells were cultured with or 
without stimuli during 1, 7, 14 and 21 days. Median values are represented in the graphs. *p<0.05,. CLCN7 - 
Chloride channel, voltage-sensitive 7; Unstim - unstimulated condition; Stim - stimulated condition.  
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CTSK gene encodes for a protease predominantly expressed by OCs which is involved in the 
degradation of the bone organic matrix, that consists mainly of type 1 collagen (Novack and 
Teitelbaum 2008). 
There were no significant differences in the CTSK expression between groups in the studied time- 
points. 
 When cells were cultured without any stimuli, the baseline group showed a peak of CTSK 
expression at day 14 (p<0.0001) whereas in follow-up and healthy groups CTSK expression continues 
to increase over time until day 21 (follow-up p=0.0001; healthy p=0.0012) as shown in Fig.III.24, left 
panel.  
In the stimulated condition, the three groups exhibit the same expression pattern over time, with the 
highest CTSK expression levels at day 14 (baseline p<0.0001; follow-up p=0.0002; healthy p=0.0003) 
(Fig.III.24, right panel). 
 
 
Figure III.24 - CTSK relative expression in cultured cells of ankylosing spondylitis patients at baseline of anti-TNF 
therapy, follow-up six months after starting the therapy and healthy donors. Cells were cultured with or without 
stimuli during 1, 7, 14 and 21 days. Median values are represented in the graphs. CTSK - Cathepsin K; Unstim - 
unstimulated condition; Stim - stimulated condition. 
 
 
No correlation was found between any of the study parameters and clinical data. 
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IV. DISCUSSION 
 
 
 
AS is characterized by syndesmophyte formation and increased BMD in the lumbar spine. In 
patients under TNF-blocking treatment a reduction of CTX-I levels was reported (Arends, Spoorenberg 
et al. 2012), which might reflect a decrease in osteoclast activity. Therefore, we hypothesized that 
there is an impairment in osteoclastogenesis in AS patients with active disease, that seems to be 
further inhibited by TNF-blocking therapy. 
The aim of this study was to understand how anti-TNF therapy regulates inflammatory environment 
in AS patients. Moreover we wanted to understand TNF-blocking effects on OC differentiation and 
activity in AS patients.  
To achieve these goals, we recruited AS patients with active disease (median ASDAS of 3.4, 
BASDAI of 5.5 and BASFI of 5.89; Table III.1) who were starting TNF-blocking therapy (baseline 
patients) and a second sample was collected six months later (follow-up patients). 
Patients had a median age of 41 years with 10 years of symptoms duration (Table III.1). Were 
predominantly males, as was previously reported by Feldtkeller et al that AS affects mainly young 
adults at around 26 years of age and is more common in men than women, at a ratio of 2:1 
(Feldtkeller, Khan et al. 2003). Fifty percent of AS patients were positive for the antigen HLA-B27 
which corroborates the hypothesis that other genes may be involved in the pathophysiology of this 
disease (Zambrano-Zaragoza, Agraz-Cibrian et al. 2013). It has been shown that TNF-blocking agents 
are an effective and well-tolerated treatment for reducing clinical symptoms of AS (Ren, Li et al. 2013) 
and, concordantly, we observed that TNF-blocking therapy decreases the levels of the inflammatory 
markers ESR and CRP and also decreases the disease and functional indexes, ASDAS, BASDAI and 
BASFI (Tables III.1 and III.2). As control group, we recruited age and gender matched healthy donors 
without inflammation. To attain the objective of this thesis a blood sample was collected from these 
patients before and 6 months after they start TNF-blocking therapy in order to assess the 
concentration of inflammatory cytokines in the serum and to isolate and differentiate osteoclasts in 
vitro.  
We have studied pro- and anti-inflammatory cytokines, which are known to be involved in AS 
pathogenesis and in osteoclast differentiation (Gratacos, Collado et al. 1994; Appel, Loddenkemper et 
al. 2009). Serum levels of IL-6, IL-1β, TNF, IL-12p70, IL-17A, IL-22, IL-8, TGF-β, IFN-γ and IL-2 are all 
significantly higher in AS patients with active disease (baseline) than in healthy subjects (Figures III.1-
III.4). Taylan et al previously measured TGF-β, IL-12, IL-17, IL-6 levels and showed that these 
cytokines were significantly higher in AS patients with active disease when compared with healthy 
controls (Taylan, Sari et al. 2012). Limón-Camacho et al also measured the serum levels of IL-6, IL-
12, IL-17A, TNF-α, IFN-γ and IL-8 and these cytokines were significantly elevated in AS patients with 
active disease compared to healthy controls, in accordance with our results (Figures III.1-III.4) (Limon-
Camacho, Vargas-Rojas et al. 2012). Moreover, Zhang et al demonstrated that serum IL-22 levels are 
increased in AS patients with mild to active disease when compared with healthy controls (Zhang, Li et 
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al. 2012). Liu and colleagues also found that IL-2 expression in AS patients with mild to active disease 
was significantly higher than the healthy group (Liu, Wang et al. 2013).  
In our study, IL-1β showed higher levels at baseline AS patients than in healthy subjects (Figure 
III.1), however, as reviewed by Keller and in a more recent paper by Bal and colleagues, no significant 
differences in IL-1β levels between AS patients with active disease and healthy controls were found 
(Keller, Webb et al. 2003; Bal, Unlu et al. 2007). We also found that IL-23 levels are not significantly 
different between groups (Figure III.1) although Taylan et al. found that IL-23 levels were significantly 
higher in AS patients with active disease than in the healthy controls (Taylan, Sari et al. 2012). Our 
results show a significant increase in IL-18, not only in baseline, but also in TNF-blocker treated AS 
patients when compared with healthy controls (Figure III.3). Indeed, Sari and co-workers observed IL-
18 levels were higher in AS patients with mild to active disease with or without TNF-blocking therapy, 
however the difference was not significant (Sari, Kebapcilar et al. 2010). To our best knowledge, 
serum levels of MCP-1 and MIP-1α have never been described in AS patients before and after TNF-
blocking therapy and we observed that the levels of these two chemokines are signifcantly increased 
in AS patients at baseline when compared to the healthy subjects and no significant differences are 
observed after TNF-blocking therapy (Figure III.3). 
When the patients were paired, we found that IL-17A and TGF-β concentrations are significantly 
decreased in AS patients after TNF-blocking therapy (Figure III.9). Although no significant differences 
were found IFN-γ, IL-2, IL-8, IL-18, IL-6, IL-1β, TNF, IL-4 and IL-10 levels are also reduced in AS 
patients after TNF-blocking therapy. In accordance with our study, Limón-Camacho et al found that 
serum levels of IL-17A were significantly higher in AS patients with active disease compared with 
patients receiving TNF blockers and the same significant difference was also seen in IL-6, IFN-γ, TNF-
α and IL-8 (Limon-Camacho, Vargas-Rojas et al. 2012). In the same study, Limón-Camacho et al 
observed that serum IL-12 levels were also elevated in AS patients with active disease when 
compared with patients under TNF-blocking therapy, however in our study no differences were found 
(Figure III.2). 
The anti-inflammatory cytokines IL-4 and IL-10 are also significantly increased in AS patients at the 
baseline when compared to healthy donors, which may be due to the activation of immune cells at 
baseline, increasing the expression of all cytokines including IL-4 and IL-10. IL-4 was also found to be 
increased in AS patients with mild to active disease by Li et al (Li, Wang et al. 2013), however Xueyi 
did not find differences in IL-10 levels, before or after TNF-blocking therapy comparing to healthy 
donors (Xueyi, Lina et al. 2013).   
Our results support recent studies that suggest a role for these cytokines in the pathogenesis of AS 
(Gratacos, Collado et al. 1994; Appel, Loddenkemper et al. 2009). In fact, the levels of most cytokines 
in patients under TNF-blockers for 6 months normalize to the healthy donors levels, which indicates a 
reduction in the inflammatory environment, particularly IL-17A, a cytokine well described to be 
associated with the pathogenesis of inflammatory disorders such as AS (Mei, Pan et al. 2011; Chen, 
Chang et al. 2012) and TGF-β, an important cytokine for bone formation (Ai-Aql, Alagl et al. 2008). 
RANKL is an essential cytokine in osteoclastogenesis since it binds to RANK promoting osteoclast 
differentiation. However, RANKL also binds to OPG, which acts as a decoy receptor since it prevents 
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the RANKL-RANK binding, thereby inhibiting osteoclastogenesis (Kwan Tat, Padrines et al. 2004). In 
the serum we can only find the soluble form of RANKL (sRANKL) since the membranous form of 
RANKL is expressed on the cell surface of osteoblasts, bone marrow stromal cells, fibroblasts, 
mammary epithelial cells and activated immune system cells and can be cleaved into the soluble form 
(Wu, Humphrey et al. 2008). The sRANKL/OPG ratio is a parameter that infers OC differentiation and 
its resorptive function. Previous studies have shown discrepancies in sRANKL and OPG levels in AS 
patients. A study by Chen and co-workers showed elevated sRANKL and OPG levels in AS patients 
with active disease (Chen, Chen et al. 2010). However, Klingberg et al found recently lower sRANKL 
levels and lower sRANKL/OPG ratio in AS patients with mild to active disease (where patients under 
TNF blockers were included) when compared with healthy controls. The same study showed that in 
the group of patients under TNF-blocking therapy sRANKL levels were increased and OPG levels 
were decreased when compared to AS patients without TNF blocker (Klingberg, Nurkkala et al. 2014). 
In a study by Taylan and colleagues, AS patients with mild to active disease (where TNF-blocking 
therapy treated patients are included) show similar sRANKL levels and decreased OPG levels than 
healthy controls. In this group of patients they also found a decreased sRANKL/OPG ratio when 
compared to healthy donors. Taylan also observed that in TNF-blockers treated patients, OPG levels 
where significantly decreased leading to an increase of sRANKL/OPG ratio when compared to 
patients under conventional therapy (NSAIDs and/or DMARDs) (Taylan, Sari et al. 2012). In our 
results, although the higher sRANKL level in the baseline group, we found no significant differences in 
sRANKL, OPG or in the sRANKL/OPG ratio when comparing the three studied groups. When we 
focus on the effect of TNF-blocking therapy in the levels of sRANKL and OPG, we found that OPG 
levels are significantly decreased after TNF-blocking therapy in the paired sub-group of patients 
(Figure III.9). Accordingly, reduced OPG levels after TNF-blocking therapy might suggest an increase 
in osteoclastogenesis.  
Osteoblasts are bone-forming cells and their differentiation and function is under the control of 
several signaling pathways. The Wnt signaling pathway is essential for osteoblast differentiation 
during skeletogenesis and continues to be important in mature osteoblasts (Crockett, Rogers et al. 
2011). SOST and DKK-1 are inhibitors of this pathway and their serum levels were assessed in this 
study. Although DKK-1 levels are higher in the baseline AS patients, we found no significant 
differences in SOST or DKK-1 serum levels between the three groups (Figure III.7). It was previously 
demonstrated that TNF stimulates the expression of Wnt antagonist DKK-1 (Briolay, Lencel et al. 
2013), acting as a brake on bone formation (Pedersen, Chiowchanwisawakit et al. 2011). As a 
consequence, TNF-blocking therapy may reset DKK-1 levels to healthy levels leading to an increase 
of Wnt signaling and consequently new bone formation. Like sRANKL and OPG, serum DKK-1 and 
SOST levels are controversial. Taylan et al described that serum levels of DKK-1 and SOST were not 
different in AS patients with mild to active disease when compared to healthy controls, but patients 
under TNF-blocking treatment presented higher DKK-1 levels compared to patients under 
conventional therapy (NSAIDs and/or DMARDs) (Taylan, Sari et al. 2012). More recently, Ustun et al 
found that SOST levels are significantly lower in AS patients with inactive to active disease than in 
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healthy controls and that TNF-blocking treatment does not affect DKK-1 and SOST levels (Ustun, Tok 
et al. 2014). 
As bone turnover markers, CTX-I and P1NP were measured in patients’ serum. To assess bone 
resorption and OC function the biochemical marker CTX-I was quantified and, on the other hand, 
P1NP was quantified to assess bone formation. We observed that patients before and after TNF-
blocking therapy have similar CTX-I and P1NP serum concentrations and the levels of both bone 
turnover markers are decreased in these groups compared to the healthy group without reaching 
statistical significance (Figure III.8). Accordingly, Acebes et al found no significant differences in P1NP 
between healthy controls and AS patients (Acebes, de la Piedra et al. 1999) but recently several 
authors have described increased levels of CTX-I in AS patients with active disease when compared 
with healthy controls (Visvanathan, van der Heijde et al. 2009; Muntean, Rojas-Vargas et al. 2011). 
We cultured PBMCs from AS patients before and after TNF-blocking treatment and also from 
healthy donors to have a better understanding about how OC differentiation and function is affected in 
AS patients with active disease and the TNF-blocking therapy effects. PBMCs were cultured under M-
CSF (25 ng/mL), RANKL (50 ng/mL), dexamethasone (10 nM) and TGF-β (2.5 ng/mL) stimulation, as 
previously described by Takuma et al. Dexamethasone at <10
-8
M acts synergistically with TGF-β to 
enhance RANKL-induced osteoclast formation (Takuma, Kaneda et al. 2003). At days 7, 14 and 21 of 
culture, functional assays (TRAP staining and resorption pit assay) were performed and RNA was 
extracted. According to the literature, at day 7 we expected to see pre-osteoclasts and at days 14 and 
21 fully differentiated osteoclasts and bone resorption (Holloway, Collier et al. 2002; Husheem, Nyman 
et al. 2005). In addition, we also cultured PBMCs without any differentiation stimuli. In this 
unstimulated condition, the monocytes behavior in culture is observed since there are no cytokines to 
induce osteoclast differentiation.  
To understand how OC differentiation is influenced by the disease and therapy we perfomed 
functional assays such as TRAP staining and we observed a continuous decrease in the number of 
pre-osteoclasts from day 7 to day 21 in both unstimulated and stimulated conditions in the three 
groups, but no significant differences were found neither over time nor between groups (Figure III.12). 
Interestingly, in the unstimulated condition, we observed OCs differentiation in the three groups at 
days 14 and 21 of culture (Figure III.14). We hypothesize that when pre-osteoclasts attach to bone 
slices through integrins a signaling pathway is activated that is able to induce the expression of 
osteoclast differentiation genes. It has been previously shown that integrins transmit pro-survival 
signals when interacting with matrix-residing ligand (Stupack and Cheresh 2002) and that unoccupied 
αVβ3 integrin transmits a positive death signal regulating osteoclast apoptosis (Zhao, Ross et al. 2005). 
In 2012, Mochizuki et al suggested that cell adhesion is required for osteoclast differentiation from 
precursor and that adhesion signaling regulates RANK expression in osteoclast precursors 
(Mochizuki, Takami et al. 2012). Another study suggested that attenuation of the integrin αVβ3 pathway 
leads to inhibition of osteoclast differentiation and that there is a crosstalk between integrin β3 and M-
CSF/c-fms pathways (Jung, Han et al. 2012). We consider that cells adhesion to bone by integrins has 
an important role in OC differentiation, but further studies are required to determinate how integrins 
are able, per se, of inducing OC differentiation.  
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When PBMCs were cultured under the stimulating condition, AS patients before and after TNF-
blocking therapy reach the highest OC number inside each group at day 14 and start to decline 
thereafter (Figure III.14), which may be due to cell apoptosis. In contrast with our results, Im et al. 
found that the number of osteoclasts from AS patients with active disease cultured with M-CSF and 
RANKL were higher than those of controls and concluded that there were increased numbers of 
osteoclast precursor cells in the peripheral blood of AS patients suggesting that osteoclastogenesis is 
elevated in AS patients than in healthy controls (Im, Kang et al. 2009).  
We performed resorption assays to understand if mature OCs formed were functional. Interestingly, 
although in the unstimulated condition we found osteoclasts at day 14 and 21 in all groups (Figure 
III.14), only one follow-up patient had resorption pits at day 21 (data not shown).  
In the stimulated condition the three groups of study exhibit the same pattern of increase in the 
number of resorption pits and the percentage of resorbed area over time (Figure III.17, upper graphs). 
There are no differences in pit size between groups (Figure III.17, bottom left panel), suggesting that 
OC mobility is not affected by the disease neither by therapy. When we compare paired AS patients 
before and after TNF-blocking therapy, both the number of resorption pits and consequently the 
percentage of resorbed area are significantly increased in patients after therapy (Figure III.18), 
suggesting that TNF-blocking therapy increases the resorptive capacity of OCs.  
We then focused on the gene expression of essential and specific osteoclast genes CSF1R, 
RANK, NFATc1, Atp6v0d2, CLCN7 and CTSK. 
The M-CSF receptor is encoded by the CSF1R gene which is expressed by monocytes and OCPs 
and is essential for their proliferation and survival (Kikuta and Ishii 2013). In our study, the follow-up 
group, unstimulated at day 7 had a significantly higher expression of CSF1R and the baseline group 
had the lowest (Figure III.19, left panel). The expression of CSF1R increases until day 21 in all groups. 
Moreover, in the stimulated condition, CSF1R expression is higher at day 7 in all groups (Figure III.19, 
right panel). Overall, our results indicate that monocytes and pre-osteoclasts of AS patients under 
TNF-blocking therapy have an increased CSF1R expression. To the best of our knowledge there has 
been no study regarding CSF1R expression in AS patients, however Li and colleagues have found in 
arthritic mice that TNF increased not only CSF1R expression in monocytes, but also the number of 
these osteoclast precursors in vivo (Li, Schwarz et al. 2004). These results further support the findings 
that in psoriatic arthritis TNF-blocking therapy reduces the number of osteoclast precursors (Ritchlin, 
Haas-Smith et al. 2003).  
RANK is the gene that encodes the receptor for RANKL present on monocytes, OCPs and mature 
OCs. Its function is to stimulate OC differentiation (Kwan Tat, Padrines et al. 2004) and according to 
previous studies TNF increases RANK expression (Kitaura, Sands et al. 2004). We analyzed RANK 
expression and we observed that at day 1 is significantly increased in healthy subjects and also in 
baseline patients when compared with the follow-up group. No other significant differences were found 
between groups in both conditions. In the stimulated condition, when we analyzed RANK expression 
throughout time we found that the healthy group has its highest RANK expression at day 1, the follow-
up group at day 7 and the baseline group at day 14 of culture (Figure III.20, right panel). Interestingly 
we found no RANK expression in the stimulated condition at day 21 of healthy donors. According to 
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our results and to these findings, RANK expression or function may be affected in monocytes and 
osteoclast precursors of AS patients. SNPs in RANK have previously been associated with 
osteoporosis (Styrkarsdottir, Halldorsson et al. 2008) and recently Cortes et al. related a RANK SNP 
with cervical damage protection given by mSASSS (Cortes, Maksymowych et al. 2014).  
NFATc1 is the target gene for RANK signaling cascade and has been proposed to function as the 
master transcription factor in osteoclastogenesis (Takayanagi, Kim et al. 2002). We found that its 
expression is significantly higher in healthy subjects at day 1 when compared to AS follow-up patients. 
Although no significant differences were observed between groups in the both unstimulated and 
stimulated conditions (Figure III.21) TNF-blocking therapy seems to increase NFATc1 expression, 
favoring osteoclastogenesis. 
Atp6v0d2 gene encodes the subunit d2 of the functional domain v0 of the ATPase proton pump 
present at the osteoclasts ruffled border and, therefore,  is responsible for extracellular acidification of 
the resorption lacunae and bone demineralization during bone resorption (Qin, Cheng et al. 2012). 
According to our results, Atp6v0d2 expression at day 1 is significantly higher in the healthy group 
when compared to follow-up patients (Figure III.22) and at day 14 in the unstimulated condition there 
is a significantly higher Atp6v0d2 expression in the follow-up group when compared to the healthy 
controls. Moreover, in the stimulated condition, both baseline and healthy groups have their higher 
Atp6v0d2 expression at day 14, and in the follow-up group Atp6v0d2 expression continues to increase 
until day 21 (Figure III.22). Although not significantly, increased Atp6v0d2 expression at days 14 and 
21 in osteoclasts of patients under TNF-blocking therapy is in accordance with our previous 
observations of increased bone resorption after anti-TNF therapy. 
CLCN7 encodes for the chloride channel that maintains osteoclasts' electroneutrality and provides 
the chloride conductance required for an efficient proton pump (Novack and Teitelbaum 2008). At day 
1, CLCN7 expression is significantly higher in healthy subjects when compared to the follow-up group. 
In the unstimulated condition gene expression at day 7 in the follow-up group is significantly higher 
when compared to baseline patients, however, at day 14 baseline patients have the highest 
expression when compared to the healthy group (Figure III.23, left panel). Thus, our results show that 
during osteoclast differentiation at days 7 and 14, TNF-blocking therapy seems to decrease CLCN7 
expression closer to the healthy expression (Figure III.23). To the best of our knowledge this gene was 
never described in ankylosing spondylitis patients but loss-of-function mutations in CLCN7 lead to 
osteopetrosis (Frattini, Pangrazio et al. 2003). 
Cathepsin K is enconded by CTSK gene and is a protease predominantly expressed by OCs which 
is involved in the degradation of the bone organic matrix (Novack and Teitelbaum 2008). When cells 
are cultured with differentiation stimuli, we found that CTSK expression significantly increases in all 
groups until day 14 (Figure III.24, right panel). Despite the differences are not significant, CTSK 
expression in osteoclasts is similar between healthy subjects and patients under TNF blockers being 
decreased in baseline AS patients at days 14 and 21 which may suggest that TNF-blocking therapy 
resets CTSK expression towards a higher osteoclast activity and bone resorption. Accordingly, serum 
levels of cathepsin K in AS patients were measured by Wendling et al and they found that levels of 
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cathepsin K were higher in AS patients with active disease than in healthy controls but the differences 
were not statistically significant (Wendling, Cedoz et al. 2008). 
Overall, our results show that expression of RANK, NFATc1, Atp6v0d2 and CLCN7 is increased in 
monocytes of healthy subjects when compared with AS patients treated or not with TNF blockers. In 
AS patients at baseline we observed lower osteoclastogenesis and, consequently, lower bone 
resorption; however in AS patients after TNF-blocking therapy osteoclast activity is increased 
suggesting that after biological treatment AS patients started to respond to osteoclastogenic stimuli, 
following what happens in the healthy control condition.  
In this study, patient recruitment was conditioned by the start of TNF-blocking therapy and 
specifically in the follow-up group, it was conditioned by biological therapy switch, which occurs when 
patients have adverse effects or are non-responders. Our results interpretation was also limited 
because we do not have dual-energy X-ray absorptiometry (DXAs) of these patients to assess their 
bone mineral density in order to correlate with our results. The functional assays also have a few 
limitations. In the TRAP staining, osteoclast precursors have the tendency to aggregate and it is 
challenging to visually distinguish multinucleated osteoclast from several mononuclear pre-
osteoclasts. In the resorption pits assay, it is difficult to distinguish between a single pit and more than 
one pit that are close together. Another limitation in assaying osteoclast function in vitro is that we 
have to infer OC behaviour from two separate cultures (one for TRAP staining and the other for pit 
assay, in both cells were cultured in bone slices). 
It has been reported that AS patients have decreased bone mineral density (Singh, Nimarpreet et 
al. 2013) but controversially these patients are also particularly prone to develop syndesmophytes, a 
bony growth originating inside a ligament and enthesitis, an inflammation at the sites where tendons or 
ligaments insert to bone (Lories and Schett 2012). However, recent studies found that in AS, even with 
TNF inhibition, ectopic bone formation is still observed, suggesting that additional factors are 
governing this effect (Osta, Benedetti et al. 2014). TNF-blocking therapy also seems to decrease 
DKK-1 levels, which might lead to increased osteoblastogenesis and bone formation (Korkosz, 
Gasowski et al. 2014) and therefore it would be interesting to study the effects of this biological 
therapy in osteoblast activity. In this study we used in vitro techniques to understand a systemic effect 
of the disease and therapy on osteoclast formation and function, which does not allow us to observe 
the interaction between osteoclasts and osteoblasts on bone remodeling. Further studies are 
necessary to address this topic. 
It has been described in other rheumatic diseases such as psoriasis changes in serum microRNAs 
levels after TNF-blocking therapy (Pivarcsi, Meisgen et al. 2013). Regarding AS, it has been found 
three highly expressed microRNAs in T cells of AS patients but none directly involved with 
osteoclastogenesis (Lai, Yu et al. 2013). Hence it would be very interesting to evaluate if there are 
microRNAs specific of AS with the ability of repressing osteoclast differentiation and function and if 
TNF-blocking therapy affects their expression. 
In light of our results we can speculate about the existence of a mechanism in AS patients that 
disconnects inflammation and osteoclastogenesis that is halted by the TNF-blocking therapy. In 
conclusion, decreased pro-inflammatory cytokine levels, in particular IL-17A and TGF-β, in AS patients 
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on TNF-blocking therapy suggest that TNF-blocking therapy resolves inflammation in AS patients. 
However, according to our results, osteoclast activity is significantly increased in AS patients under 
TNF blockers. Moreover, OPG levels are decreased after TNF-blocking therapy. Therefore, the 
present study points to an increase in osteoclastogenesis and also in bone resorption in AS patients 
under TNF-blocking therapy. 
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Criteria for AS diagnosis: 
Table VI.1 - 1984 Modified New York criteria for ankylosing spondylitis. Adapted from (National Institute for Health 
and Care Excellence 2008) 
Modified New York criteria for diagnosis of ankylosing spondylitis 
A definite diagnosis of ankylosing spondylitis requires the radiological criterion and at least one clinical 
criterion to be satisfied as defined below. 
Radiological criterion 
 Sacroiliitis at least grade 2 bilaterally or grade 3 or 4 unilaterally. 
Clinical criteria 
 Low back pain and stiffness for more than 3 months that improves with exercise but is not 
relieved by rest. 
 Limitation of motion of the lumbar spine in both the sagittal and frontal planes. 
 Limitation of chest expansion relative to normal values correlated for age and sex. 
All reasonable measures should be taken to ensure that symptoms are due predominantly to ankylosing 
spondylitis and that alternative causes, including spinal fracture, disc disease and fibromyalgia, are 
excluded. 
 
  
 Radiographs of the sacroiliac joint can appear normal in the early phase of disease since it can 
take up to 10 years for structural changes to become visible on plain radiographs (Schett, Coates et 
al. 2011). To identify AS patients early before irreversible structural damage has occurred, at the time  
treatment should be started, other imaging techniques such as magnetic resonance imaging (MRI) 
have to be used since they allow the detection of inflammation in the sacroiliac joints in patients early 
in the course of the disease when no chronic changes are detectable (Coates, Marzo-Ortega et al. 
2010). 
 
 
Criteria for starting TNF-blocking therapy: 
Anti-TNF therapy is only used in cases of active disease (Bath Ankylosing spondylitis disease 
activity index (BASDAI) > 4 and expert opinion), refractory to conventional therapy such as 
physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs), failure of intra-articular steroids (if 
indicated) and failure of sulfasalazine (if predominant peripheral arthritis) (Coates, Marzo-Ortega et al. 
2010). 
For patients with active AS with symptoms of pain, stiffness and decrease of function, TNF-
blocking therapy is significantly effective and increasingly considered the standard of care when 
patients fail to respond adequately to conventional treatment with NSAIDs at the maximum possible 
dose and physical exercises (Khan 2011). The finding that TNF is present at high concentrations in 
sacroiliac joints of AS patients (Braun, Bollow et al. 1995) provided a strong guideline for the use of 
TNF-inhibitors, which have proven to be very successful in the treatment of spondyloarthritides (Ren, 
Li et al. 2013).  
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Table VI.2 - Characteristics of primers used in this study 
Gene  Sequence Ta Transcript 
CSF1R 
Fw GAACATCCACCTCGAGAAGAAA 
60ºC 88 bp 
Rv GACAGGCCTCATCTCCACAT 
RANK 
Fw GAACATCATGGGACAGAGAAATC 
60ºC 89 bp 
Rv GGCAAGTAAACATGGGGTTC 
NFATc1 
Fw GCAAGCCGAATTCTCTGGTG 
60ºC 144 bp 
Rv TACCGTTGGCGGGAAGGTAG 
Atp6v0d2 
Fw CATTCTTGAGTTTGAGGCCG 
60ºC 186 bp 
Rv CCGTAATGATCCGCTACGTT 
CLCN7 
Fw CGAGTCGGACATATGAGCAG 
60ºC 83 bp 
Rv TCCTTGGGGAAGGGATGT 
CTSK 
Fw GCCAGACAACAGATTTCCATC 
60ºC 75 bp 
Rv CAGAGCAAAGCTCACCACAG 
18s rRNA 
Fw GGAGTATGGTTGCAAAGCTGA 
60ºC 129 bp 
Rv ATCTGTCAATCCTGTCCGTGT 
CSF1R - Colony stimulating factor 1 receptor; RANK - Receptor activator of NF-kB; NFATc1 - Nuclear factor 
of activated T cells cytoplasmic 1; Atp6v0d2 - ATPase; CLCN7 - Chloride channel, voltage-sensitive 7; CTSK 
- cathepsin K; rRNA - ribossomal ribonucleic acid; Fw - forward; Rv - reverse; Ta - Annealing temperature; 
bp - base pair. 
 
 
